Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Venrock Adviser, LLC

CIK 0001615982
$2.68B
Reported AUM
33
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Venrock Adviser, LLC · Q1 2026

AI · grounded in 13F

Venrock Adviser, LLC established a new position in DMRA valued at $93.3M. The fund also opened new stakes in RLMD for $33.7M and TENX for $26.8M. Conversely, the fund closed its entire position in UPB, resulting in a $31.7M reduction.

Portfolio · Q1 2026

APGE$714.9MERAS$265.1MORKA$203.5MSYRE$185.9MKALVDNTHDMRAOCULCOGTVRDNSVRAELVNOther$603.8MVL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1APGEAPOGEE THERAPEUTICS INC$134.09-0.16%255.38%484.81%$714.9M26.68%HELD
2ERASERASCA INC$18.15-2.84%1243.88%-21.87%$265.1M9.89%HELD
3ORKAORUKA THERAPEUTICS INC$96.51-1.38%619.56%390.71%$203.5M7.60%HELD
4SYRESPYRE THERAPEUTICS INC$98.33-3.12%524.23%-44.00%$185.9M6.94%HELD
5KALVKALVISTA PHARMACEUTICALS INC$130.3M4.86%HELD
6DNTHDIANTHUS THERAPEUTICS INC$106.92-5.08%447.06%10.00%$99.0M3.70%HELD
7DMRADAMORA THERAPEUTICS INC$28.99-0.75%811.39%-73.74%$93.3M3.48%HELD
8OCULOCULAR THERAPEUTIX INC$8.17-3.54%-31.50%-22.68%$87.6M3.27%HELD
9COGTCOGENT BIOSCIENCES INC$38.93-5.88%248.33%379.59%$77.0M2.87%HELD
10VRDNVIRIDIAN THERAPEUTICS INC$18.92-4.92%14.30%48.73%$75.9M2.83%HELD
11SVRASAVARA INC$5.46-1.44%113.90%257.42%$75.0M2.80%HELD
12ELVNENLIVEN THERAPEUTICS INC$54.811.59%192.63%186.06%$67.7M2.53%HELD
13ORICORIC PHARMACEUTICALS INC$11.07-4.90%15.02%-47.31%$54.7M2.04%HELD
14VORVOR BIOPHARMA INC$21.15-2.98%-51.02%-93.00%$54.3M2.03%HELD
15MAZEMAZE THERAPEUTICS INC$26.92-2.57%85.44%125.92%$47.8M1.78%HELD
16CTMXCYTOMX THERAPEUTICS INC$3.10-5.49%33.40%-38.77%$46.9M1.75%HELD
17JBIOJADE BIOSCIENCES INC$19.75-1.25%190.28%-96.57%$45.2M1.69%HELD
18DYNDYNE THERAPEUTICS INC$25.18-2.14%150.55%48.73%$39.4M1.47%HELD
19CBIOCRESCENT BIOPHARMA INC.$14.47-3.66%25.17%-106.15%$39.2M1.46%HELD
20ZURAZURA BIO LTD$5.43-1.99%260.00%-20.70%$38.3M1.43%HELD
21RLMDRELMADA THERAPEUTICS INC$5.31-0.75%800.00%-77.79%$33.7M1.26%HELD
22ENGENE HOLDINGS INC$32.5M1.21%HELD
23TENXTENAX THERAPEUTICS INC$13.70-9.27%142.77%-99.41%$26.8M1.00%HELD
24ANLADLAI NORTYE LTD$13.000.00%796.55%61.49%$22.2M0.83%HELD
25IPSCCENTURY THERAPEUTICS INC$2.02-7.76%311.65%-91.17%$19.7M0.73%HELD
26CGEMCULLINAN THERAPEUTICS INC$16.50-5.82%115.25%-41.50%$19.6M0.73%HELD
27HELPCYBIN INC$7.82-3.93%3.44%-92.65%$18.5M0.69%HELD
28SRZNSURROZEN INC$22.216.63%101.91%-80.97%$18.4M0.69%HELD
29SEPNSEPTERNA INC$34.45-2.08%182.15%36.22%$12.2M0.45%HELD
30KRROKORRO BIO INC$10.37-0.77%-24.55%-97.29%$11.4M0.43%HELD
31ANROALTO NEUROSCIENCE INC$27.07-5.45%$11.2M0.42%HELD
32ARTVARTIVA BIOTHERAPEUTICS INC$10.10-3.16%$10.4M0.39%HELD
33XFORX4 PHARMACEUTICALS INC$3.98-0.50%$1.4M0.05%HELD

Source: SEC EDGAR · accession 0001615982-26-000011. 13F discloses long positions only — shorts, foreign equities, and options are excluded.